Resource impact statement
Cancer Drugs Fund technology
NICE has recommended crizotinib for use within the Cancer Drugs Fund for treating ROS1-positive advanced non-small-cell lung cancer.
Crizotinib will be available to the NHS in line with the managed access agreement with NHS England. As part of this, NHS England and Pfizer have a commercial access agreement that makes crizotinib available to the NHS at a reduced cost. The financial terms of the agreement are commercial in confidence.
The resource impact of crizotinib will be covered by the Cancer Drugs Fund budget. The guidance will be reviewed by the date the managed access agreement expires April 2023 or when the results of the managed access agreement data collection are available, whichever is sooner. The aim of the review is to decide whether or not the drug can be recommended for routine use. Further information can be found in NHS England’s Appraisal and Funding of Cancer Drugs from July 2016 (including the new Cancer Drugs Fund) - A new deal for patients, taxpayers and industry.
Around 40 people each year with ROS1-positive advanced non-small-cell lung cancer are eligible for treatment with Crizotinib.
This technology is commissioned by NHS England. Providers are NHS hospital trusts.
This page was last updated: 04 July 2018